Daiichi Sankyo Co Ltd
TSE:4568
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3 825
6 148
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Daiichi Sankyo Co Ltd
Daiichi Sankyo Co Ltd
PP&E Net
Daiichi Sankyo Co Ltd
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
PP&E Net
¥458.4B
|
CAGR 3-Years
17%
|
CAGR 5-Years
14%
|
CAGR 10-Years
4%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
PP&E Net
¥1.9T
|
CAGR 3-Years
9%
|
CAGR 5-Years
5%
|
CAGR 10-Years
13%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
PP&E Net
¥578.8B
|
CAGR 3-Years
6%
|
CAGR 5-Years
5%
|
CAGR 10-Years
6%
|
|
|
S
|
Shionogi & Co Ltd
TSE:4507
|
PP&E Net
¥121.1B
|
CAGR 3-Years
7%
|
CAGR 5-Years
10%
|
CAGR 10-Years
4%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
PP&E Net
¥426.4B
|
CAGR 3-Years
9%
|
CAGR 5-Years
11%
|
CAGR 10-Years
12%
|
|
|
Astellas Pharma Inc
TSE:4503
|
PP&E Net
¥309.7B
|
CAGR 3-Years
5%
|
CAGR 5-Years
4%
|
CAGR 10-Years
5%
|
|
Daiichi Sankyo Co Ltd
Glance View
Daiichi Sankyo Co., Ltd., a prominent player in the global pharmaceuticals sector, has cemented its position as a leader through innovation and strategic expansion. Founded in 2005 from the merger of Daiichi Pharmaceutical and Sankyo Company, the company has continually focused on research and development, particularly in the fields of oncology, cardiovascular medicine, and vaccines. This dedication has resulted in a robust pipeline of transformative therapies, including the highly anticipated antibody-drug conjugates that address unmet medical needs. Investors are drawn to Daiichi Sankyo not just for its impressive portfolio but also for its commitment to quality and sustainability, underpinned by a strong financial foundation that supports ongoing growth. As the global healthcare landscape evolves, Daiichi Sankyo is well-prepared to adapt and capitalize on emerging opportunities, such as the accelerating demand for personalized medicine and innovative treatment modalities. The company's strategic partnerships and collaborations, particularly with international giants, have further bolstered its reach and resource capacity, making it a formidable force in the industry. For investors, this dynamic blend of innovative prowess, strategic foresight, and sound financial management makes Daiichi Sankyo an attractive option, promising potential long-term growth as it continues to push the boundaries of what's possible in healthcare.
See Also
What is Daiichi Sankyo Co Ltd's PP&E Net?
PP&E Net
458.4B
JPY
Based on the financial report for Sep 30, 2024, Daiichi Sankyo Co Ltd's PP&E Net amounts to 458.4B JPY.
What is Daiichi Sankyo Co Ltd's PP&E Net growth rate?
PP&E Net CAGR 10Y
4%
Over the last year, the PP&E Net growth was 20%. The average annual PP&E Net growth rates for Daiichi Sankyo Co Ltd have been 17% over the past three years , 14% over the past five years , and 4% over the past ten years .
You don't have any saved screeners yet
